Boston Scientific, Cook to develop paclitaxel-coated stents under deal with Angiotech.
This article was originally published in The Gray Sheet
Executive Summary
BOSTON SCIENTIFIC, COOK TO EVALUATE PACLITAXEL-COATED STENTS under a three-way development pact with pharmaceutical firm Angiotech. According to terms of the deal, announced July 10, Boston Scientific and Cook each will take a 2% stake in Vancouver-based Angiotech and will make subsequent milestone payments that could make the deal worth as much as 32 mil. Canadian dollars ($23.3 mil. USD). Under the agreement, Angiotech licenses to BSC and Cook the use of paclitaxel, an anti-cancer drug, and related compounds as a coating for stents "and other endoluminal devices" used to treat vascular and gastrointestinal diseases, Angiotech says.
You may also be interested in...
Boston Scientific v. Cook
Ruling on summary judgement motions is slated for June 6 in the firms' dispute over the license of paclitaxel-coating technology from Cook to Guidant for its Achieve drug-coated stent, according to Boston Scientific. No trial would be required for issues decided on summary judgement by the Northern Illinois federal court. Boston Scientific alleges that the licensing agreement violates a co-exclusive agreement for the technology reached with Canadian firm Angiotech Pharmaceuticals and Cook in 1997 (1"The Gray Sheet" July 14, 1997, I&W-1). The court has dismissed a Cook claim of unfair trade practices but declined to dismiss Cook's anti-trust claim, according to Boston Scientific. Guidant maintains that its agreement with Cook establishes a legal distributor relationship with the privately held firm...
Boston Scientific v. Cook
Ruling on summary judgement motions is slated for June 6 in the firms' dispute over the license of paclitaxel-coating technology from Cook to Guidant for its Achieve drug-coated stent, according to Boston Scientific. No trial would be required for issues decided on summary judgement by the Northern Illinois federal court. Boston Scientific alleges that the licensing agreement violates a co-exclusive agreement for the technology reached with Canadian firm Angiotech Pharmaceuticals and Cook in 1997 (1"The Gray Sheet" July 14, 1997, I&W-1). The court has dismissed a Cook claim of unfair trade practices but declined to dismiss Cook's anti-trust claim, according to Boston Scientific. Guidant maintains that its agreement with Cook establishes a legal distributor relationship with the privately held firm...
Boston Scientific Disputes Cook Collaboration With Guidant On Coated Stents
Favorable six-month results from a Cook 21-patient, paclitaxel-coated coronary stent pilot study, including zero restenosis, appear to bode well for the larger ELUTES European study. Six-month ELUTES data are slated to be released at the American Heart Association meeting in November.